Skip to content

uniQure QURE Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
Beam Therapeutics logo
Beam TherapeuticsBEAM

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's accrued expenses and other liabilities?
uniQure (QURE) reported accrued expenses and other liabilities of $3.9M in Q1 2026.
How has uniQure's accrued expenses and other liabilities changed year-over-year?
uniQure's accrued expenses and other liabilities increased by 423.5% year-over-year, from -$1.21M to $3.9M.